Roche wins approval for cancer drug Kadcyla in fast-growing China market - (London South East via NewsPoints Desk)

  • Roche announced on Wednesday that Chinese regulators have approved the import of its antibody-drug conjugate Kadcyla to treat breast cancer, as reported by London South East.

  • Specifically, Kadcyla is approved in China as an adjuvant treatment for patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and treatment based on Roche's Herceptin.

  • The therapy had been granted priority review status in June last year by China's National Medical Product Administration, official records show.

  • The news source said that over a decade, China has gone from Roche's 10th biggest market to its second-largest behind the US, with 4.5 billion Swiss francs in 2018 sales, as more of its advanced medicines won Chinese regulatory clearance. 

  • The pace has accelerated, with growth in China topping 50% over the first nine months of 2019, about double the rate in 2018, the news source added.

To read more NewsPoints articles, click here.